IgGenix Announces First Patient Dosed in Phase 1 Clinical Trial “ACCELERATE Peanut” Evaluating IGNX001 in Peanut Allergy
Novel SEQ SIFTER™ discovery platform used to re-engineer original human IgE antibodies into IgG antibodies to block binding and protect against peanut allergen
Topline data expected in mid-2025
Excerpt from the Press Release:
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2024 /PRNewswire/ — IgGenix, Inc., a clinical-stage biotechnology company pioneering innovative treatments for immune mediated diseases, announced today the first patient dosed in its ACCELERATE Peanut Phase 1 clinical trial. The trial aims to evaluate IGNX001, a novel therapeutic candidate developed using IgGenix’s proprietary SEQ SIFTER platform, in patients with peanut allergy. Designed to neutralize the most clinically important peanut allergens and epitopes, IGNX001 represents a novel approach to combat peanut allergies by blocking the allergic cascade.
“We are thrilled to announce the initiation of our ACCELERATE Peanut Phase 1 clinical trial and the dosing of our first participant,” said Jessica Grossman MD, CEO of IgGenix. “IGNX001 embodies years of rigorous research and development, and this milestone marks an important step toward validating our mechanism of action in allergy treatment. Preclinical data have demonstrated the potential of IGNX001 to have greater impact for patients living with peanut allergy, particularly through its expected rapid onset of action, improved safety profile, and less frequent subcutaneous injection schedule. We look forward to reporting topline data in mid-2025 and progressing IGNX001 through the clinic.”
The ACCELERATE Peanut Phase 1 trial is a randomized, multi-center, double-blind, placebo-controlled, single ascending dose study designed to assess the safety, tolerability, and potential proof of mechanism of IGNX001 in peanut-allergic individuals. Targeting both adults and older adolescents (ages 15 to 18), the study will enroll approximately 24 participants who have been diagnosed with peanut allergies. Details of the study can be found at https://clinicaltrials.gov/study/NCT06331728.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?